## Biomarker Changes after Strenuous Exercise Can Mimic Pulmonary Embolism and Cardiac Injury– A Metaanalysis of 45 Studies

Farbod Sedaghat-Hamedani,<sup>1,2</sup> Elham Kayvanpour,<sup>1,2</sup> Lutz Frankenstein,<sup>1</sup> Derliz Mereles,<sup>1,2</sup> Ali Amr,<sup>1,2</sup> Sebastian Buss,<sup>1</sup> Andreas Keller,<sup>4</sup> Evangelos Giannitsis,<sup>1</sup> Katrin Jensen,<sup>3</sup> Hugo A. Katus,<sup>1,2</sup> and Benjamin Meder<sup>1,2\*</sup>

**BACKGROUND:** Biomarkers are well established for diagnosis of myocardial infarction [cardiac troponins, highsensitivity cardiac troponins (hs-cTn)], exclusion of acute and chronic heart failure [B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP)] and venous thromboembolism (D-dimers). Several studies have demonstrated acute increases in cardiac biomarkers and altered cardiac function after strenuous sports that can pretend a cardiovascular emergency and interfere with state-of-the-art clinical assessment.

METHODS: We performed a systematic review and metaanalysis of biomarker and cardiovascular imaging changes after endurance exercise. We searched for observational studies published in the English language from 1997 to 2014 that assessed these biomarkers or cardiac function and morphology directly after endurance exercise. Of 1787 identified abstracts, 45 studies were included.

**RESULTS:** Across all studies cardiac troponin T (cTnT) exceeded the cutoff value (0.01 ng/mL) in 51% (95% CI, 37%–64%) of participants. The measured pooled changes from baseline for high-sensitivity cTnT (hs-cTnT) were +26 ng/L (95% CI, 5.2–46.0), for cTnI +40 ng/L (95% CI, 21.4; 58.0), for BNP +10 ng/L (95% CI, 4.3; 16.6), for NT-proBNP +67 ng/L (95% CI, 49.9; 84.7), and for D-dimer +262 ng/mL (95% CI, 165.9; 358.7). Right ventricular end diastolic diameter increased and right ventricular ejection fraction as well as the ratio of the early to late transmitral flow velocities decreased after exercise, while no significant changes were observed in left ventricular ejection fraction.

Received March 13, 2015; accepted June 18, 2015.

**CONCLUSIONS:** Current cardiovascular biomarkers (cTnT, hs-cTnT, BNP, NT-proBNP, and D-dimer) that are used in clinical diagnosis of pulmonary embolism, acute coronary syndrome, and heart failure are prone to alterations due to strenuous exercise. Hence, it is necessary to take previous physical exercise into account when a cardiac emergency is suspected.

© 2015 American Association for Clinical Chemistry

The positive impact of exercise on cardiovascular and all-cause mortality has been well described. However, strenuous exercise has also been shown to cause notable perturbation in blood chemistry (1). It is estimated that 25 out of every 1000 marathon runners seek medical care after competition (2). Exercise-associated collapse  $(EAC)^5$  is, with rates of 59%–85%, the most common cause seen in the medical tent after prolonged endurance exercise (3). Although EAC is usually benign, it can be life threatening in some cases (4). Over the past several years, numerous studies have evaluated the effects of strenuous exercise on blood concentrations of cardiac biomarkers and hemostatic proteins. Additionally, exercise-induced changes in left ventricular (LV) and right ventricular (RV) functions were also noticed in different studies (5). This issue is of clinical importance because increases in biomarkers after strenuous sports may severely confound the interpretation of biomarker results in athletes presenting acutely to an emergency department and also raise the question for the exact pathomechanism of release when structural and functional dysfunction has been excluded. Many but not all studies suggest that strenuous physical exertion may indeed result in myocardial injury (6). The incidence of biomarker altera-

<sup>&</sup>lt;sup>1</sup> Department of Medicine III, University of Heidelberg, Heidelberg, Germany; <sup>2</sup> DZHK (German Centre for Cardiovascular Research), Germany; <sup>3</sup> Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; <sup>4</sup> Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.

<sup>\*</sup> Address correspondence to this author at: Department of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany. Fax +49(0)6221-564486; e-mail Benjamin.Meder@med.uni-heidelberg.de.

Previously published online at DOI: 10.1373/clinchem.2015.240796

<sup>© 2015</sup> American Association for Clinical Chemistry

<sup>&</sup>lt;sup>5</sup> Nonstandard abbreviations: EAC, exercise-associated collapse; LV, left ventricular; RV, right ventricular; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal proBNP; PE, pulmonary embolism; HF, heart failure; ACS, acute coronary syndrome; DVT, deep vein thrombosis; hs-cTnT, high-sensitivity cardiac troponin T; cMRI, cardiac MRI; EF, ejection fraction; RVEDD, RV-end diastolic diameter; E/A ratio, ratio of early (E) to late (A) transmitral flow; tPA, tissue plasminogen activator; LGE, late gadolinium enhancement.

tions [cardiac troponin, D-dimer, B-type natriuretic peptide (BNP), and N-terminal proBNP (NT-proBNP)] and changes in cardiac function, however, vary strongly among these studies. In particular, the small sample sizes in many of these studies may cause imprecise estimation of the postexercise change in biomarkers or cardiac function.

Cardiac troponins are the preferred markers for the diagnosis of acute myocardial infarction but may also be measured in patients with pulmonary embolism (PE) and other acute life-threatening complications including heart failure (HF) and arrhythmias (7). The early diagnosis of these conditions is essential, because immediate treatment is associated with improved prognosis (8). Moreover, an increase in cardiac troponin has been frequently reported to be associated with worse prognosis in patients with acute coronary syndrome (ACS) but also in other acute non-ACS conditions affecting the cardiovascular system such as PE, acute HF, and myocarditis, and ACS measurement has been recommended in the clinical routine (7). Plasma D-dimer is used clinically to exclude venous thromboembolism with a high negative predictive value (9). Circulating concentrations of BNP or NT-proBNP are directly related to the severity of ventricular dysfunction, and values below decision cutoffs are used to exclude acute or chronic HF. Furthermore, natriuretic peptides confer prognostic information in patients with PE and HF (10). RV dilation can be observed in about 25% of patients with PE, and the absence of signs of RV overload or dysfunction excludes PE as a cause of hemodynamic instability in patients with shock or hypotension and is one important marker for decision-making regarding systemic lysis therapy (8).

Increased concentrations of biomarkers can also be observed in other conditions outside their intended use. For instance, clinical specificity of cardiac troponins has decreased at the expense of improved sensitivity. Although cardiac tissue is the exclusive source of cardiac troponin in blood, myocardial injury may also occur in the absence of an ACS (11). Therefore, analytically true-positive increases in troponin concentrations in the absence of ACS are frequent and may confound the correct diagnosis. A huge list of reasons has been compiled taking into consideration potential mechanisms of myocardial injury. Likewise, the negative predictive values of natriuretic peptides and D-dimers are hampered by abnormal values owing to confounders (12).

Combining existing studies in a metaanalysis provides a higher sample size and consequently more precise estimates of biomarker and ventricular parameter changes. We first report a case of a healthy woman who was admitted to our emergency room with suspected PE immediately after participating in a marathon. Next, we report the metaanalysis results of a systematic review we performed to explore the changes in cardiac biomarkers (cardiac troponin, BNP, and NT-proBNP), D-dimer, RV, and LV function after strenuous exercise.

### CASE

A 35-year-old female amateur marathon runner was admitted to the emergency room of university hospital Heidelberg because of collapse after running about 10 km in the heat of the summer. The athlete was conscious at presentation. She had no family history of cardiovascular diseases, PE, or deep vein thrombosis (DVT) and she was not pregnant. Blood glucose and electrolyte concentrations were within reference intervals. However, laboratory tests showed an increased high-sensitivity cardiac troponin T (hs-cTnT) of 73 ng/L (99th percentile, 14 ng/L; Roche Diagnostics) and a D-dimer concentration of 9920 ng/mL (reference interval, <500 ng/mL). The electrocardiogram showed a sinus tachycardia (107 bpm) with no significant ST-segment abnormalities. The echocardiography showed normal RV and LV function. Three hours later, the hs-cTnT concentration increased to 149 ng/ mL. Meanwhile, PE was ruled out using computed tomography angiography. Seven hours later, the hscTnT concentration decreased to 97 ng/L. To exclude myocardial injury, a decision was made to perform a noninvasive procedure, cardiac MRI (cMRI). This showed a LV ejection fraction (EF) of 71% with no signs of myocardial scar or ischemia. One day later, the hs-cTnT concentration decreased to 32 ng/L. Exercise stress test, pulmonary function test, carotid ultrasound, and 24-h Holter monitoring showed no pathological findings. After 4 days of uneventful inpatient monitoring, the patient was discharged from our clinic and her collapse and increase in cTnT were interpreted as a consequence of dehydration during the marathon.

### Methods

### STUDY DESIGN AND SEARCH STRATEGY

We performed a systematic review and metaanalysis of observational studies published in English from 1997 to 2014. The metaanalysis was performed according to PRISMA (the Preferred Reporting of Items for Systematic reviews and MetaAnalysis) *(13)*. We searched for all prospective or case control studies in which cTnT, cTnI, BNP, NT-proBNP, D-dimer, or cardiac imaging data were evaluated before and after strenuous exercises. We searched the PubMed, EMBASE, ScienceDirect, and SportDiscus databases. Reference lists of original publications and review articles were also carefully reviewed. Key words were "Marathon," "Triathlon," "Exercise," "Troponin," "D-dimer," "Brain Natriuretic Peptide," "NT-proBNP," "Echocardiography," "CMRI," "Cardiac biomarkers," "Athletes," and "Exercise induced cardiac damage."

# SELECTION OF ARTICLES, DATA EXTRACTION, AND QUALITY ASSESSMENT

We assessed the effects of exercise on cTnT, cTnI, BNP, NT-proBNP, D-dimer, RV-end diastolic diameter (RVEDD), RV-EF, LV-EF, and ratio of early (E) to late (A) transmitral flow (E/A ratio) in human adults within 24 h after completion of exercise. We excluded case reports, review articles, and studies without reference interval values for troponin. Positive values for cTnT and hs-cTnT were defined above 0.01 ng/mL or 14 ng/L, respectively.

Of the 1718 identified articles, 1644 were excluded on the basis of review of the title and abstract (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol61/issue10). Two reviewers (F. Sedaghat-Hamedani and E. Kayvanpour) independently assessed full texts of 74 remaining manuscripts. Twenty-nine of these were excluded as case reports (3), review articles (5), and metaanalyses (3). Two had different cutoff values for cTnT, 13 included insufficient information, and 2 were repeated studies. We assessed the quality of the eligible studies using the NHLBI (National Heart, Lung and Blood Institute) quality assessment tool for before-after (pre-post) studies with no control group (14). Disagreements between reviewers were resolved by discussion or by consensus including a third author. For 45 final identified studies, data were extracted, including author, year, sample size, age and sex, type of exercise, biomarkers, mean duration of exercise time, exercise distance, detection assay, and mean values measured before and after exercise, as well as imaging data (see online Supplemental Tables 1-8). For each cTnT (with conventional assay and high-sensitivity assay), cTnI, BNP, NT-proBNP, D-dimer, RV diameter, RV-EF, LV-EF, and E/A ratio data were separately extracted and analyzed. For cTnT, 33; for hs-cTnT, 4; for cTnI, 12; for BNP, 7; for NTproBNP, 17; for D-dimer, 7; for RVEDD, 8; for RV-EF, 7; for LV-EF, 21; and for E/A ratio, 16 studies were included (see online Supplemental Fig. 1). For cTnT we excluded the study of Fortescue et al. with a large number of individuals (483 runners) owing to their pooled evaluation of cTnT and cTnI (18). All studies were analyzed in a single pool with pre- and postexercise design without a control group.

### OUTCOMES

For all extracted biomarkers the mean "change from baseline" for each study was derived as the difference between the mean final and the mean baseline values with their SEs. Medians with ranges or interquartile ranges were converted into means with SDs as described by Hozo et al. (16). The SE of the change from baseline was obtained by the extracted P value for the comparison between pre- and postvalues using normal approximation (17). If a P value was missing, we imputed the change-from-baseline SE using the baseline and final SDs and an assumed correlation coefficient between pre- and postvalues of 0.3 (17). For the biomarkers cTnT and hs-cTnT the "frequency of increase above the cutoff value" was defined as the proportion of individuals with final concentration exceeding a common cutoff value (for cTnT above 0.01 ng/mL and for hs-cTnT above 14 ng/L).

#### STATISTICAL ANALYSIS

Using the meta package (version 3.1-2) in R (version 3.0.2, The R Foundation for Statistical Computing, 2013), random effects metaanalyses of the changes from baseline and the frequency of increase above the defined cutoff value were conducted. A positive change from baseline represents a higher final biomarker value in comparison to the baseline value. The higher the "frequency of increase above the cutoff value," the higher the proportion of participants with a biomarker exceeding this cutoff value after endurance exercise. Heterogeneity was quantified by  $I^2$  statistics. In the case of heterogeneity, we also performed sensitivity and subgroup analyses to investigate potential clinical and methodological heterogeneity. The presence of publication bias was addressed, although not explored, by funnel plots and tests of asymmetry because the assumption of an underlying symmetric distribution is not reasonable for the changes from baseline in this clinical setting.

### Results

#### CARDIAC BIOMARKERS CAN INCREASE AFTER STRENUOUS EXERCISE

We analyzed cTnT, hs-cTnT, and cTnI separately. Thirty-three studies, which included a total of 1045 athletes, evaluated changes in cTnT concentration after strenuous exercise. The overall frequency of increase above the cutoff value for cTnT (values above 0.01 ng/ mL) after exercise was 51% (95% CI, 37-64) (Fig. 1). However, there was large, statistically significant heterogeneity between studies ( $I^2$ , 97.3%; P < 0.0001). Four studies evaluated hs-cTnT after physical exertion. In these studies the overall frequency of increase above the cutoff value (values above 14 ng/L) was 83% (95% CI, 70-95) (see online Supplemental Fig. 2). The mean concentration of hs-cTnT before exercise was 4 ng/L (95% CI, 3.0-4.8), which increased to 32 ng/L (95% CI, 13.5-49.6). The change from baseline for hs-cTnT before and after physical exertion was 26 ng/L (95% CI, 5.2-46.0) (Fig. 2). For cTnI, 12 studies, which included

	Exercise mode	male	remale	Mean age (years)	Mean duration (min)	Events	Iotal	Proportion	95% CI
pple 2002	Marathon	7	12	38	289	10	19		0.53 (0.29-0.76
shave 2003	Marathon	0	7	44	374	3	7		0.43 (0.10-0.82
George 2004	Marathon	-	2	-	256	26	33		0.79 (0.61-0.91
Vhyte 2005	Marathon	43	9	35	254.3	32	39		- 0.82 (0.66-0.92
eers 2006	Marathon	25	2	48		9	27		0.33 (0.17-0.54
1iddleton 2006	Marathon	13	1	29	212	9	13		0.69 (0.39-0.91
leilan 2006	Marathon	41	19	41	-	38	60		0.63 (0.50-0.75
aenz 2006	Marathon	-	-	49	250	21	30		0.70 (0.51-0.85
rassl 2008	Marathon	0	15	35	256	8	15		0.53 (0.27-0.79
assal 2009	Marathon	44	24	42	310	36	68		0.53 (0.40-0.65
nebel 2009	Marathon	28	0	63	270	8	28		0.29 (0.13-0.49
nebel 2009	Marathon	50	0	46	247	22	50		0.44 (0.30-0.59
lingels 2009	Marathon	70	15	47	228	38	85		0.45 (0.34-0.56
lousavi 2009	Marathon	8	6	33	245	14	14		
arlstedt 2012	Marathon	21	4	55	259	25	25	-	
aker 2014	Marathon			-	(area)	34	50		0.68 (0.53-0.80
nebel 2014	Marathon	0	54	43.2	263.9	19	54		0.35 (0.23-0.49
nebel 2014	Marathon	0	35	55.3	278.5	13	35		0.37 (0.21-0.55
ippi 2008	Half marathon	17	0	47	93	0	17		0.00 (0.00-0.20
assal 2009	Half marathon	40	21	40	150	28	61		0.46 (0.33-0.59
omah 2010	Half marathon	7	8	-		15	15		
0hba 2001	Ultramarathon	10	0	46	661	10	10		
shave 2002	Ultramarathon	26	0	41	850	13	26		0.50 (0.30-0.70
shave 2004	Triathlon	9	0	33	301	4	9		0.44 (0.14-0.79
ulloh 2006	Triathlon	36	2	38	684.4	32	38		- 0.84 (0.69-0.94
have 2004	Cycling	8	0	28.2	254	2	8 -	- 100	0.25 (0.03-0.65
have 2004	Cycling	8	0	33.5	125	1	8 —	101	0.12 (0.00-0.53
awson 2005	Cycling	16	õ	31	240	2	16 -		0.12 (0.02-0.38
have 2002	Running	8	0	29	30	0	8		0.00 (0.00-0.37
iddleton 2007	Running	10	0	33	139.9	4	10		0.40 (0.12-0.74
George 2004	Rugby and football	19	0	21		0	19		0.00 (0.00-0.18
charhag 2005	Marathon/ultramarathon/MBM	92	13	38.8	113.2	49	105		0.47 (0.37-0.57
leumayr 2005	Mountain bike marathon	29	0	34	550	13	29		0.45 (0.26-0.64
andom effects mod	del							-	0.51 (0.37-0.64

Fig. 1. Forest plot of the frequency of increase above the cutoff value for cTnT (above 0.01 ng/L).

Studies are ranked by publication year and exercise mode [Apple et al. (2002)(*59*), Baker et al. (2014)(*47*), Dawson et al. (2005)(*39*), George et al. (2004)(*37*), George et al. (2004)(*57*), Frassl et al. (2008)(*22*), Jassal et al. (2009)(*53*), Karlstedt et al. (2012)(*50*), Knebel et al. (2012)(*48*), Knebel et al. (2009)(*52*), Leers et al. (2006)(*55*), Lippi et al. (2008)(*49*), Middleton et al. (2006)(*25*), Middleton et al. (2007)(*60*), Mingels et al. (2009)(*51*), Mousavi et al. (2009)(*21*), Neilan et al. (2006)(*24*), Neumayr et al. (2005)(*20*), Ohba et al. (2001)(*45*), Oomah et al. (2010)(*46*), Scharhag et al. (2005)(*36*), Saenz et al. (2006)(*54*), Shave et al. (2002)(*38*), Shave et al. (2004)(*40*) Shave et al. (2004)(*41*), Shave et al. (2002)(*44*), Shave et al. (2003)(*58*), Tulloh et al. (2006)(*42*), Whyte et al. (2005)(*56*)]. Jassel et al. (2009), Knebel et al. (2009), and Knebel et al. (2012) performed analyses in 2 different patient cohorts and are thus mentioned twice each. MBM, mountain bike marathon. Hyphens indicate data not available.

412 individuals, were evaluated. The mean cTnI concentration before exercise was 18 ng/L (95% CI, 6.4–29.7) vs 67 ng/L (95% CI, 49.0–84.2) after exercise, with a change from baseline of 40 ng/L (95% CI, 21.4–58.0) (Fig. 3). For cTnI, evident heterogeneity between studies was again observed. These heterogeneities could be explained because of differences in training status and performance of participants, different types of exercise with diverse intensity, and different time of blood sample taking after exercise, as well as different cardiac troponin assays used.

In 17 studies, which included 835 individuals, NT-proBNP changes after strenuous exercise were analyzed, with a change from baseline of 67 ng/L (95% CI, 49.9–84.7) (Fig. 4A). For BNP, 7 studies, which included 200 individuals, were evaluated. The BNP increase was less pronounced than for NT-proBNP, with a change from baseline of 10 ng/L (95% CI, 4.3–16.6) (Fig. 4B). The statistical heterogeneities for NT-proBNP and BNP were lower than those in troponin studies with  $I^2$ , 66.1% (P < 0.0001) and  $I^2$ , 76.9% (P < 0.0002), respectively. Performing subgroup analyses for exercise type could not reduce heterogeneities in different studies investigating biomarker changes after endurance exercise.

# D-DIMER INCREASES SIGNIFICANTLY AFTER ENDURANCE SPORTS

D-Dimer, a product of fibrin degradation with high negative predictive value in ruling out DVT and PE, was evaluated in 7 studies, which included 146 individuals. Six studies in marathon and 1 study in ultramarathon runners analyzed the changes in concentration of D-dimer before and after the race. Altogether,

### hs-cTnT

Study	Exercise mode	Male	Female	Mean age (years)	Mean duration (min)	Total	Change from baseline	95% CI
Scherr 2011	Marathon	102	0	42	227	102		27.76 (11.23-44.29)
Baker 2014*	Marathon	-	-			50		42.00 (16.98-67.02)
Aagaard 2014	Running	42	0	50.7	-	42		35.80 (14.48-57.12)
Wedin 2015	Floorball	23	0	19		23	-	4.95 (2.00-7.90)
Random effects mod	lel							25.64 (5.24-46.05)
Heterogeneity: /2 = 86.6%,	, $\tau^2 = 353.3$ , $P < 0.0001$					- 		
						-40	-20 0 20 40 60	80

Fig. 2. Change from baseline (in ng/L) for hs-cTnT after endurance exercise is given.


Studies are ranked by publication year and exercise mode [Aagaard et al. (2014)/62), Baker et al. (2014)/47), Scherr et al. (2011)/63), Wedin et al. (2015)/61]. \*, In this study hs-cTnT concentration before the race was lower than the detection limit (3 ng/L), because the authors' mean was given as 3 with an SD of 0. Hyphens indicate data not available.

D-dimer increased significantly after exercise, with a change from baseline of 262 ng/mL (95% CI, 165.9–358.7). These studies were not significantly heterogeneous (Fig. 5).

# STRENUOUS EXERCISE CAN CAUSE ACUTE DYSFUNCTION OF THE RV, BUT NOT THE LV


Finally, the effect of strenuous exercise on RV function was analyzed in 7 studies (232 individuals) with echocardiography and in 5 studies (96 individuals) with cMRI. RV-EF and RVEDD changes in cMRI and echocardiography were measured separately. LV-EF changes were measured in 17 studies (501 individuals) with echocardiography and in 4 studies (82 individuals) with cMRI. RVEDD increased and RV-EF decreased after exercise, whereas no significant changes were observed in LV-EF.

The increase of RVEDD measured in cMRI with a change from baseline of 12.1 mm (95% CI, 3.5-20.8) was more evident than in echocardiography, with a change from baseline of 3.7 (95% CI, -0.7 to 8.00) (Fig. 6A). For RVEDD, no heterogeneity was observed in cMRI; however, in echocardiography significant statistical heterogeneity was seen ( $I^2$ , 83.1%; P < 0.0001). The RV-EF transiently decreased from before to after the endurance sports, with a change from baseline of -7.0%(95% CI, -14.4 to 0.3) in echocardiography and -8.6% (95% CI, -16.4 to -0.7) in cMRI (Fig. 6B). The change from baseline for LV-EF in echocardiography was -2.1% (95% CI, -3.6 to -0.7) compared with 1.9% (95% CI, 0.9-2.9) in cMRI (see online Supplemental Fig. 3). In addition, a decrease of E/A ratio, as an index of LV diastolic filling, was observed immedi-



### Fig. 3. cTnI change from baseline after endurance exercise (in ng/L).

Studies are ranked by publication year and exercise mode [Baker et al. (2013), Banfi et al. (2010) (70), Eijsvogels et al. (2014) (23), Frassl et al. (2008) (23), La Gerche et al. (2012) (5) Legaz-Arrese et al. (2011) (68), O'Hanlon et al. (2010) (69), Salvagno et al. (2014) (65), Serrano Ostariz et al. (2013) (64), Shave et al. (38) (2002), Smith et al. (2004) (71), Trivax et al. (2010) (70)]. \*, In this study cTnl was lower than the detection limit (20 ng/L) at any stage of the study. Hyphens indicate data not available.



#### Fig. 4. NT-proBNP (A) and BNP (B) changes from baseline after endurance exercise (in ng/L).

Studies are ranked by publication year and exercise mode. (A), Aagaard et al. (2012) (72), Banfi et al. (2010) (69), Frassl et al. (2008) (22), Knebel et al. (2009) (52), Leers et al. (2006) (55), Legaz-Arrese et al. (2011) (67), Lippi et al. (2008) (49), Middleton et al. (2006) (25), Neilan et al. (2006) (24), Neumayr et al. (2005) (20), O'Hanlon et al. (2010) (68), Salvagno et al. (2014) (65), Serrano Ostariz et al. (2013) (64), (22), Scherr et al. (2011) (63), Serrano Ostariz et al. (2013) (64), (22), Scherr et al. (2011) (63), Serrano Ostariz et al. (2013) (64). (B), Baker et al. (2014) (47), Frassl et al. (2008) (22), La Gerche et al. (2012) (5), Leers et al. (2006) (55), Ohba et al. (2001) (45), Saenz et al. (2006) (54), Trivax et al. (2010) (70). Hyphens indicate data not available.

ately after exercise in 16 included studies. The change from baseline of E/A ratio in echocardiography was -0.4 (95% CI, -0.5 to -0.3) (see online Supplemental Fig. 4).

#### Discussion

Numerous studies have reported the increase of cardiac biomarkers such as cardiac troponin, BNP, and NTproBNP after exercise. The presence or increase of such cardiac biomarkers usually reflects myocardial injury and HF in cardiac patients. In this study we performed a systematic review and metaanalysis of studies that evaluated biomarkers and cardiac function before and after strenuous exercise. We demonstrated a statistically significant increase of cardiac troponin, BNP, NT-proBNP, and D-dimer after exercise. As illustrated by the case report in this review, these acute changes in biomarkers and cardiac function after endurance exercise such as marathon and triathlon running can lead to hospital admission and extensive invasive and noninvasive procedures.

Most studies showed significant cardiac troponin increases after exercise. We showed that overall about 51% of individuals had cTnT concentrations that were at least mildly increased above the limit of detection of thirdgeneration cardiac troponin assays (0.01 ng/mL). The metaanalyses of Shave et al. (including 26 studies) and Regwan et al. (including 16 studies) demonstrated results similar to those of our study (including 33 studies), with overall rates of 47% and 51%, respectively (6, 17). The large observational study of Fortescue et al. reported that almost 68% of 482 runners in the Boston Marathon showed cTnT or cTnI increases (18). It should be noted that the previous metaanalysis of Shave et al. included this study in their analysis as an estimation of cTnT increase, which is not totally accurate, as Fortescue et al. did not discriminate between cTnT and cTnI. Altogether, in approximately one-half of participants cTnT concentra-

### D-Dimer

Study	Exercise mode	Male	Female	Mean age (years)	Mean duration (min)	Total	Change from baseline	95% CI
Prisco 1998	Marathon	12	0	35	165	12		475.25 (113.63-836.87)
Smith 2004	Marathon	27	7	38	241	34		319.70 (129.27-510.13)
Saenz 2006	Marathon	-	-	49	250	30		445.50 (180.14-710.86)
Sumann 2007	Marathon	12	1	-	223	13		144.00 (0.00-288.00)
Parker 2012	Marathon	12	6	32	222	18		148.00 (23.31-272.69)
Parker 2012	Marathon	12	11	42	214	23		245.00 (0.00-490.00)
Kupchak 2013	Ultramarathon	12	4	44.6	1478.4	16		371.00 (150.02-591.98)
Random effects m	CARGE REAL LINE HARD REAL REAL PROPERTY IN						\$	262.27 (165.86-358.69)
Heterogeneity: I <sup>2</sup> = 38.4	\$%, τ <sup>2</sup> = 6158, <i>P</i> = 0.1361					Г		7
						-400	-200 0 200 400 600 8001	000

Fig. 5. D-Dimer change from baseline after endurance exercise in ng/mL.

Studies are ranked by publication year and exercise mode [Kupchak et al. (2013) (28), Parker et al. (2012) (73), Prisco et al. (1998) (27), Saenz et al. (2006) (54), Smith et al. (2004) (71), Sumann et al. (2007) (26)]. Parker et al. (2012) analyzed 2 different patient cohorts and are thus mentioned twice. Hyphens indicate data not available.

tion postexercise exceeds 0.01 ng/mL and 83% of individuals show an increase in hs-cTnT above the 99th percentile (14 ng/L). The exercise-induced increase in troponin could be due to release of cytoplasmic cTnT and cTnI, because exercise may increase membrane permeability of cardiomyocytes (19, 20). This reversible membrane leakage might be due to increased mechanical stress on the cardiomyocytes, overload with free radicals, increased body temperature, or prolonged acidosis (19, 21).

BNP and NT-proBNP are mostly released from cardiac ventricles in response to volume or pressure overload and myocardial strain (22). These cardiac peptides are powerful biomarkers to identify patients with HF or other causes of wall stress. High concentrations of BNP or NT-proBNP in patients with PE, ACS, and HF are associated with increased mortality (23). The significant increase of BNP and NT-proBNP seems a result of changes in diastolic filling (24). Increase of end-diastolic pressure due to increased cardiac output during prolonged exercise can also release BNP and NT-proBNP (25). In our analysis, the increase of NT-proBNP is more substantial than BNP. This may be due to different elimination patterns of these proteins/peptides. The half-life of BNP is about 20 min, vs 120 min for NT-proBNP, and BNP is mainly eliminated through endopeptidases, whereas the elimination of NT-proBNP is mainly through glomerular filtration (22).

D-Dimer as a primary enzymatic degradation product of fibrin is broadly used as a biomarker with a high negative predictive value in patients with suspected PE, DVT, and acute aortic syndrome (26-28). This metaanalysis demonstrated significant increase of D-dimer after strenuous exercise, which may mimic a thrombotic event in the clinical setting. Physical exertion leads to activation of platelets, coagulation, and fibrinolysis (29). Fibrinolysis may result from release of tissue plasminogen activator (tPA) (1). Catecholamine, vasopressin, or epinephrine release, hypoglycemia, thrombin increase, vascular sheer stress, and muscular injury, which can occur during physical exertion, may release tPA from vascular endothelial cells and lead to increases in D-dimer concentrations (1, 28). It should be mentioned, however, that different assays have been used in different studies for cTnI, BNP, and D-dimer, which makes pooling problematic. None of the included studies provided the percentage of increase above the upper reference interval and the corresponding SE and, therefore, this percentage could not be extracted and pooled in the metaanalysis. As a result of this limitation we pooled the changes from baseline according to each assay used.

It is well known that acute PE can lead to RV dilation and failure, which predicts a worse prognosis (30, 31). In contrast, several studies reported transient depression of RV systolic function and RV dilation after endurance sports without prognostic consequences (5, 21, 24). These transient changes may be due to exercise-induced pulmonary hypertension or volume load (21). The increase of RVEDD was more evident in cMRI measurements (change from baseline, 12.1 mm) in comparison to echocardiography (change from baseline, 3.7 mm). Because cMRI may be more accurate in the estimation of RV volumes and function than cardiac ultrasound, the change from baseline calculated on the basis of cMRI should be more reliable than echocardiography (32). An acute LV dysfunction was not observed, because LV-EF did not significantly change after endurance sport in most studies. Regarding LV-EF, our results were similar to the previous results from Middleton et al., who performed a metaanalysis of LV function in 18 studies reported between 1984 and 2005 (33). They interpreted the -1.9% (95% CI, -1.0 to -2.9) mean change

Nellar 2006 Marathon 41 19 41 - 60 Knebel 2009 Marathon 50 0 46 247 50 Marathon 50 0 46 247 50 Marathon 50 0 46 247 50 -1.00 (-2.89-0.89) Musavi 2009 Marathon 8 6 33 245 14 	Study	Exercise mode	Male	Female	Mean ag	e (years	) Mean	duration (min)	Total	Chang	e from baseline	95% CI	
Knebel 2009       Marathon       28       0       63       270       28      2.90 (-5.2-0.28)         Knebel 2009       Marathon       8       6       33       245       14      1.00 (-2.890.89)         Mousav 2009       Marathon       21       4       55       259       25      1.01 (-0.28)      1.01 (-0.28)         Somah 2010       Marathon       21       4       55       259       25      1.01 (0.00-28.00)         Somah 2010       Half marathon       7       8       -       -       15       11.00 (0.00-28.00)         Somah 2010       Half marathon       7       8       -       -       15       11.00 (0.00-28.00)         Study       Exercise mode       Male Female Mean age (years) Mean duration (min) Total       Change from baseline       95% CI         Echocardiography       Oomah 2010       Half marathon       7       8       -       -       15       -	Echocardiography									Ĩ			
Knobel 2009       Marathon       50       0       46       247       50       -1       100 (-2.89-0.89)         Karlstedt 2012       Marathon       21       4       55       259       25       18.00 (2.83-33.17)         Ormah 2010       Half marathon       7       8       -       -       15       10.00 (0.00-20.00)         Standom effects model       Heterogeneity: P=83.1%, r2=19.16, P < 0.0001	Neilan 2006	Marathon						-			-#-		
Mousavi 2009 Marathon 8 6 33 245 14 Marathon 21 4 55 259 25 Random effects model Heterogenetity: <i>P</i> = 0%, <i>r</i> <sup>2</sup> = 0, <i>P</i> = 0.7412 B RV-EF Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95%, Cl Echocardiography Ormah 2010 Half marathon 7 8 15 - 15	Knebel 2009	Marathon	28		6	3		270	28	-		-2.90 (-5.520.28)	
Karlsteit 2012 Marathon 21 4 55 259 25 16 18.00 (2.83-33.17) Random effects model Heterogeneity: P= 0%, +1= 10.6, P < 0.0001 MRI Karlsteit 2012 Marathon 7 8 - 21 4 55 259 25 16 14.00 (0.00-28.00) MRI Karlsteit 2012 Marathon 7 8 - - 15 15 16.0 (-0.66-8.00) 11.00 (0.00-28.00) 12.15 (3.50-20.79) -20 -10 0 10 20 30 40 B RV-EF Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Comah 2010 Half marathon 7 8 - - 15 - Gerche 2012 Marathon/triathion/cycling/ultra triathion 36 4 37 - Change from baseline 95% CI -14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -5.00 (-10.00-0.00) -7.03 (-11.40-0.34) Heterogeneity: P= 29%, +1 = 11.73, P = 0.2354 MRI MRI MRI Karlsteit 2012 Marathon 12 13 38.7 256 25 - -8.10 (-12.18-4.00 -20.000 11.0 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-11.40-0.34) Heterogeneity: P= 29%, +1 = 11.73, P = 0.2354 MRI MRI MRI MRI Karlsteit 2012 Marathon 12 13 38.7 256 25 - -8.10 (-12.18-4.00 -2.00 (-44.00-0.00) -1.00 (-28.00-0.00) -7.03 (-11.40-0.34) Half marathon 7 8 - - 15 - -8.10 (-12.18-4.00 -2.00 (-44.00-0.00) -1.00 (-28.00-0.00) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-12.18-4.00 -2.00 (-44.00-0.00) -1.00 (-28.00-0.00) -7.03 (-10.00-0.00) -7.03 (-10.00-0.00) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.03 (-11.40-0.34) -7.00 (-22.00 (-44.00-0.00) -7.00 (-20.00-0.00) -7.00 (-20.00-0.	Knebel 2009	Marathon	50	0	4	8		247	50	*		-1.00 (-2.89-0.89)	
Domah 2010 Half marathon 7 8 Random effects model Heterogeneity: P = 0%, r <sup>1</sup> = 19.16, P < 0.0001 MRI Karlstedt 2012 Marathon 21 4 55 259 25 The model Half marathon 7 8 15 Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Oomah 2010 Half marathon 7 8 15 Echocardiography Oomah 2010 Marathon 12 13 38.7 256 25	Mousavi 2009	Marathon	8	6	3	3		245	14	ł		8.00 (0.00-16.00)	
Random effects model Heterogeneity: <i>P</i> = 83.1%, r <sup>1</sup> = 19.16, <i>P</i> < 0.0001 MRI Karlstedt 2012 Marathon 21 4 55 259 25 Domah 2010 Half marathon 7 8 - 15 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 0, <i>P</i> = 0.7412 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 0, <i>P</i> = 0.7412 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 0, <i>P</i> = 0.7412 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 0, <i>P</i> = 0.7412 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 0, <i>P</i> = 0.7412 Heterogeneity: <i>P</i> = 0%, r <sup>1</sup> = 1, 73, <i>P</i> = 0.2354 MRI MRI Karlstedt 2010 Marathon 12 13 38.7 256 25 Heterogeneity: <i>P</i> = 2%, r <sup>1</sup> = 11.73, <i>P</i> = 0.2354 MRI MRI MRI MRI MRI MRI MRI MRI	Karlstedt 2012	Marathon	21	4	5	5		259	25			18.00 (2.83-33.17)	
Heterogeneity: P = 83.1%, 1 <sup>2</sup> = 19.16, P < 0.0001 MRI Karlstedt 2012 Marathon 21 4 55 259 25 The model Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 0%, 1 <sup>2</sup> = 0, P = 0.7412 Heterogeneity: P = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: P = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: P = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: P = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 73, P = 0.2354 Heterogeneity: H = 2%, 1 <sup>2</sup> = 11, 1 <sup>3</sup> , 1 <sup>3</sup> = 0, 2 <sup>3</sup> = 1 <sup>3</sup> =	Oomah 2010	Half marathon	7	8					15	ł		10.00 (0.00-20.00)	
Heterogeneity: $P = 83.1\%$ , $1^2 = 19.16$ , $P < 0.0001$ MRI Karlstedt 2012 Marathon 21 4 55 259 25 The model Heterogeneity: $P = 0\%$ , $1 = 0$ , $P = 0.7412$ Heterogeneity: $P = 0\%$ , $1 = 0$ , $P = 0.7412$ The model Heterogeneity: $P = 0\%$ , $1 = 0$ , $P = 0.7412$ B RV-EF Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Comah 2010 Half marathon 7 8 15	Random effects mode	1								+	0	3,67 (-0.66-8.00)	
Karistedt 2012 Marathon 21 4 55 259 25 Domah 2010 Half marathon 7 8 15 Random effects model Heterogeneity: P = 0%, + = 0, P = 0.7412 B RV-EF Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Oomah 2010 Half marathon 7 8 15 Gerche 2012 Marathon/triathlon/cycling/ultra triathlon 36 4 37 - 40 Random effects model MRI Trivax 2010 Marathon 12 13 38.7 256 25 	Heterogeneity: /2 = 83.1%,	$\tau^2 = 19.16, P < 0.000$	1										
Domah 2010 Half marathon 7 8 Random effects model Heterogeneity: <i>P</i> = 0%, <i>z</i> ! = 0, <i>P</i> = 0.7412 B RV-EF Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Oomah 2010 Half marathon 7 8 15 Gerche 2012 Marathon/triathion/cycling/ultra triathion 36 4 37 - 40 Fitiva 2010 Marathon 12 13 38.7 256 25 Triva 2010 Marathon 17 0 33.5 209 17 Triva 2010 Marathon 17 0 33.5 209 17 Change from baseline 95% CI 	MRI												
Domah 2010       Half marathon       7       8       -       15       11.00 (0.00-22.00)         Random effects model       Heterogeneity: P = 0%, + = 0, P = 0.7412       -20       -10       0       10       20       30       40         B RV-EF         Study       Exercise mode       Male Female Mean age (years) Mean duration (min) Total       Change from baseline       95% CI         Echocardiography       Oomah 2010       Half marathon       7       8       -       -       15       -14,00 (-28.00-0.00)         Gerche 2012       Marathon/triathlon/cycling/ultra triathlon       36       4       37       -       40       -       -       -       -       -       -       -       -       -       -       0       -	Karlstedt 2012	Marathon	21	4	5	5		259	25	-		14.00 (0.00-28.00)	
Random effects model Heterogeneity: <i>I<sup>P</sup></i> = 0%, + <sup>2</sup> = 0, <i>P</i> = 0.7412 <b>B RV-EF</b> Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Oomah 2010 Haif marathon 7 8 - 15 - 14,00 (-28.00-0.00) Gerche 2012 Marathon/triathion/cycling/ultra triathion 36 4 37 - 40 - 15,00 (-10.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) MRI Trivax 2010 Marathon 12 13 38.7 256 25 	Oomah 2010	Half marathon		8					15	-			
Heterogeneity: $P = 0\%$ , $r^2 = 0$ , $P = 0.7412$ <b>B RV-EF</b> Study Exercise mode Male Female Mean age (years) Mean duration (min) Total Change from baseline 95% CI Echocardiography Oomah 2010 Half marathon 7 8 - 15 - 15 - 140 - 1400 (-28.00-0.00) Gerche 2012 Marathon/triathlon/cycling/ultra triathlon 36 4 37 - 40 - 140 - 500 (-10.00-0.00) Random effects model Heterogeneity: $P = 0.2354$ MRI Trivax 2010 Marathon 12 13 38.7 256 25 8.10 (-12.184.00) O'Hanlon 2010 Marathon 7 8 - 15 15 15	Random effects mode	1											
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heterogeneity: $I^2 \approx 0\%$ , $\tau^2$	= 0, P = 0.7412											
Comah 2010         Half marathon         7         8         -         -         15         -         -         14.00 (-28.00-0.00)         -         -         500 (-10.00-0.00)         -         -         500 (-10.00-0.00)         -         -         -         40         -         -         -         -         -         40         -	3 RV-EF								-20	0 -10 0	10 20 30	40	
Comah 2010         Half marathon         7         8         -         -         15         -         -         14.00 (-28.00-0.00)         -         -         500 (-10.00-0.00)         -         -         500 (-10.00-0.00)         -         -         -         40         -         -         -         -         -         40         -	B RV-EF	Exe	ercise	mode		Male	Female	Mean age (yea					95% CI
Gerche 2012         Marathon/triathlon/cycling/ultra triathlon         36         4         37         -         40         -         -         5.00 (-10.00-0.00)         -         -         -         5.00 (-10.00-0.00)         -         -         -         5.00 (-10.00-0.00)         -         -         -         5.00 (-10.00-0.00)         -         -         -         5.00 (-10.00-0.00)         -         -         -         -         -         5.00 (-10.00-0.00)         - <td>Study</td> <td>Exe</td> <td>ercise</td> <td>mode</td> <td></td> <td>Male</td> <td>Female</td> <td>Mean age (yea</td> <td></td> <td></td> <td></td> <td></td> <td>95% CI</td>	Study	Exe	ercise	mode		Male	Female	Mean age (yea					95% CI
Random effects model       -7.03 (-14.40-0.34)         Heterogeneity: I <sup>2</sup> = 29%, r <sup>1</sup> = 11.73, P = 0.2354       -7.03 (-14.40-0.34)         MRI       Trivaz 2010       Marathon       12       13       38.7       256       25       -8.10 (-12.184.0.74)         Mousavi 2009       Marathon       8       6       33       245       14       -22.00 (-44.00-0.00)         O'Hanlon 2010       Marathon       17       0       33.5       209       17       1.80 (-3.58-7.18)         Karlstedt 2012       Marathon       21       4       55       259       25       -21.00 (-42.00-0.00)         Oomah 2010       Half marathon       7       8       15       -31.00 (-26.00-0.00)       -31.00 (-26.00-0.00)         Random effects model       -8.56 (-16.39-0.7)       -8.56 (-16.39-0.7)       -8.56 (-16.39-0.7)       -8.56 (-16.39-0.7)	Study Echocardiography										n (min) Total		
Heterogeneity: IP = 29%, -1 = 11.73, P = 0.2354         MRI         Trivax 2010       Marathon       12       13       38.7       256       25      8.10 (-12.184.0.         Mousavi 2009       Marathon       8       6       33       245       14      22.00 (-44.00-0.00)         O'Hanion 2010       Marathon       17       0       33.5       209       17       -1.80 (-3.58-7.18)         Karistedt 2012       Marathon       21       4       55       259       25      21.00 (-42.00-0.00)         Oomah 2010       Half marathon       7       8       -15      21.00 (-42.00-0.00)         Andom effects model      8.56 (-16.390.7)      3.56 (-16.390.7)      3.56 (-16.390.7)	Study Echocardiography Oomah 2010	На	alf mar	athon	a triathlon	7	8	-			n (min) Total 15		-14.00 (-28.00-0.00)
Trivax 2010         Marathon         12         13         38.7         256         25        8.10 (-12.18,4.07)           Mousavi 2009         Marathon         8         6         33         245         14        22.00 (-44.00-0.00)           O'Hanlon 2010         Marathon         17         0         33.5         209         17         -         1.80 (-3.58-7.18)           Karistedt 2012         Marathon         21         4         55         259         25        21.00 (-42.00-0.00)           Oomah 2010         Half marathon         7         8         -         15        21.00 (-42.00-0.00)           Andom effects model         -         -         15         -         -         -	Study Echocardiography Oomah 2010 Gerche 2012	Ha Marathon/triath	alf mar	athon	a triathlon	7	8	-			n (min) Total 15		-14.00 (-28.00-0.00) -5.00 (-10.00-0.00)
Mousavi 2009         Marathon         8         6         33         245         14         -22.00 (-44.00-0.00)           O'Hanlon 2010         Marathon         17         0         33.5         209         17         1.80 (-3.58-7.18)           Karlstedt 2012         Marathon         21         4         55         259         25         -21.00 (-42.00-0.00)           Omah 2010         Half marathon         7         8         -         15         -21.300 (-26.00-0.00)           Random effects model         -         15         -         -         -         -	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode	Ha Marathon/triath	alf mar	athon	a triathlon	7	8	-			n (min) Total 15		-14.00 (-28.00-0.00)
Mousavi 2009         Marathon         8         6         33         245         14         -22.00 (-44.00-0.00)           O'Hanlon 2010         Marathon         17         0         33.5         209         17         1.80 (-3.58-7.18)           Karlstedt 2012         Marathon         21         4         55         259         25         -21.00 (-42.00-0.00)           Omah 2010         Half marathon         7         8         -         15         -21.300 (-26.00-0.00)           Random effects model         -         15         -         -         -         -	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>r</sup> = 29%, t <sup>2</sup>	Ha Marathon/triath	alf mar	athon	a triathlon	7	8	-			n (min) Total 15		-14.00 (-28.00-0.00) -5.00 (-10.00-0.00)
O'Hanlon 2010         Marathon         17         0         33.5         209         17         1.80 (-3.58-7.18)           Karlstedt 2012         Marathon         21         4         55         259         25	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode	Ha Marathon/triath I = 11.73, P = 0.2354	ilf mar Ion/cy	athon cling/ultr	a triathlon	7 36	8 4	37		n duratio - -	n (min) Total 15 40	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34)
Karlstedt 2012         Marathon         21         4         55         259         25        21.00         (-42.00-0.00)        21.00         (-42.00-0.00)	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>2</sup> = 29%, + <sup>1</sup> MRI	Ha Marathon/triath 1 = 11.73, P = 0.2354	ilf mar lon/cy Marat	athon cling/ultr hon	a triathlon	7 36 12	8 4 13	37		n duratio	n (min) Total 15 40 25	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) -8.10 (-12.184.02
Oomah 2010         Half marathon         7         8         -         -         15         -         -         -         13.00 (-26.00-0.00)           Random effects model	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>2</sup> = 29%, <sup>-1</sup> MRI Trivax 2010 Mousavi 2009	Ha Marathon/triath I = 11.73, P = 0.2354	alf mar lon/cy Marat Marat	athon cling/ultr hon hon	a triathlon	7 36 12 8	8 4 13 6	37 38.7 33		n duration - - 256 245	n (min) Total 15 40 25 14	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) -8.10 (-12.184.02 -22.00 (-44.00-0.00)
Random effects model -8.56 (-16.390.7)	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>F</sup> = 29%, t <sup>4</sup> MRI Trivax 2010	Ha Marathon/triath I = 11.73, P = 0.2354	alf mar lon/cy Marat Marat Marat	athon cling/ultr hon hon	a triathlon	7 36 12 8 17	8 4 13 6 0	37 38.7 33 33.5		n duration - - 256 245 209	n (min) Total 15 40 25 14 17	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) -8.10 (-12.184.02 -22.00 (-44.00-0.00)
	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>7</sup> = 29%, + <sup>1</sup> MRI Trivax 2010 Mousavi 2009 O 'Hanlon 2010	Ha Marathon/triath I = 11.73, <i>P</i> = 0.2354	If mar Ion/cy Marat Marat Marat	athon cling/ultr hon hon hon	a triathlon	7 36 12 8 17 21	8 4 13 6 0 4	37 38.7 33 33.5 55		n duration - - 256 245 209 259	n (min) Total 15 40 25 14 17 25	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) -8.10 (-12.184.02 -22.00 (-44.00-0.00) 1.80 (-3.58-7.18)
	Study Echocardiography Oomah 2010 Gerche 2012 Random effects mode Heterogeneity: I <sup>7</sup> = 29%, <sup>-†</sup> MRI Trivax 2010 Mousavi 2009 O'Hanlon 2010 Karlstedt 2012 Oomah 2010	Ha Marathon/triath I = 11.73, P = 0.2354 Ha	If mar Ion/cy Marat Marat Marat	athon cling/ultr hon hon hon	a triathlon	7 36 12 8 17 21	8 4 13 6 0 4	37 38.7 33 33.5 55		n duration - - 256 245 209 259	n (min) Total 15 40 25 14 17 25	Change from baseline	-14.00 (-28.00-0.00) -5.00 (-10.00-0.00) -7.03 (-14.40-0.34) -8.10 (-12.184.02 -22.00 (-44.00-0.00) 1.80 (-3.58-7.18) -21.00 (-42.00-0.00)

### Fig. 6. RV function assessment with echocardiography and MRI.

Data on RV-EF and RVEDD after endurance exercise were evaluated separately. Change from baseline for RVEDD is measured in millimeters (A) and for RV-EF in percentage (B). Studies are ranked by publication year and exercise mode [Karlstedt et al. (2012) (50), Knebel et al. (2009) (52), La Gerche et al. (2012) (5), Mousavi et al. (2009) (21), Neilan et al. (2006) (24), Oomah et al. (2010) (46), O'Hanlon et al. (2010) (68), Trivax et al. (2010) (70)]. Hyphens indicate data not available.

of LV-EF from baseline, a change which is physiologically irrelevant, as statistically significant. Regarding diastolic function, a significant reduction in E/A ratio was observed, demonstrating that diastolic filling can be compromised immediately after exercise.

Some studies reported an increase in arrhythmic disorders such as arrhythmogenic RV cardiomyopathy or atrial fibrillation among endurance athletes (34). Recent studies suggest that proarrhythmic substrates may be predominantly expressed in the RV and not in the LV after repetitive sustained exertion (5). In animal models intense exercise causes increased expression of transforming growth factor- $\beta$ 1 in the right and left atria as well as in the RV, which promotes RV-specific fibrosis (35). cMRI could show focal late gadolinium enhancement (LGE), which correlates to fibrotic areas in endurance athletes. In all of the cases, focal LGE was identified in the interventricular septum most often at the insertion site of the RV (5). These fibrotic patches, which could serve as substrates for ventricular tachyarrhythmias and sudden cardiac death, are also found in patients with cardiomyopathies (35).

In conclusion, our analysis highlights evidence that cTnT, hs-cTnT, cTnI, NT-proBNP, BNP, and D-dimer concentrations can significantly increase after endurance exercise. In addition, transient RV dilation and dysfunction can be observed. All these changes can mimic PE, ACS, HF, or cardiac injury. An accurate interpretation of increased cardiac biomarkers after strenuous exercise is thus mandatory. Serial measurements of cardiac troponin may help to differentiate between physiological and pathological changes of cardiac troponin, but, as shown in our case report, the cardiac troponin values well may mimic those for acute disease (4). Diagnosis of PE or myocardial injury after endurance sports should hence be made on the basis of all available clinical information and not on blood test results only (4, 8). Lack of awareness of this phenomenon may trigger invasive procedures and can be unnecessarily expensive and harmful. Furthermore, it would be interesting to analyze whether new biomarkers such as microRNAs can rule out pathologic myocardial injury in athletes after endurance exercise.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

- Womack CJ, Nagelkirk PR, Coughlin AM. Exerciseinduced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease. Sports Med 2003;33:795–807.
- Asplund CA, O'Connor FG, Noakes TD. Exerciseassociated collapse: an evidence-based review and primer for clinicians. Br J Sports Med 2011; 45:1157-62.
- Holtzhausen LM, Noakes TD. The prevalence and significance of post-exercise (postural) hypotension in ultramarathon runners. Med Sci Sports Exerc 1995; 27:1595–601.
- Whyte G, Stephens N, Senior R, George K, Shave R, Wilson M, Sharma S. Treat the patient not the blood test: the implications of an increase in cardiac troponin after prolonged endurance exercise. Br J Sports Med 2007; 41:613–5; discussion 615.
- La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J 2012;33:998–1006.
- Shave R, George KP, Atkinson G, Hart E, Middleton N, Whyte G, et al. Exercise-induced cardiac troponin T release: a meta-analysis. Med Sci Sports Exerc 2007;39:2099–106.
- Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol 2013;10:623–34.
- 8. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315.
- 9. Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001;135:98-107.
- Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–7.
- Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
- Pulivarthi S, Gurram MK. Effectiveness of p-dimer as a screening test for venous thromboembolism: an update. N Am J Med Sci 2014;6:491–9.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.
Consultant or Advisory Role: E. Giannitsis, Roche Diagnostics.
Stock Ownership: None declared.
Honoraria: None declared.
Research Funding: None declared.
Expert Testimony: None declared.
Patents: H.A. Katus, patent number: 6376206.

14. NHLBI, RTI International. Quality assessment tool for before-after (pre-post) studies with no control group, 2014. http://www.nhlbi.nih.gov/health-pro/guidelines/ in-develop/cardiovascular-risk-reduction/tools/beforeafter (Accessed July 2014).

References

- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
- Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester (England): John Wiley & Sons; 2008. http://onlinelibrary. wiley.com/book/10.1002/9780470712184 (Accessed August 2015).
- Regwan S, Hulten EA, Martinho S, Slim J, Villines TC, Mitchell J, Slim AM. Marathon running as a cause of troponin elevation: a systematic review and metaanalysis. J Interv Cardiol 2010;23:443–50.
- Fortescue EB, Shin AY, Greenes DS, Mannix RC, Agarwal S, Feldman BJ, et al. Cardiac troponin increases among runners in the Boston Marathon. Ann Emerg Med 2007;49:137–43, 43 e1.
- Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169–76.
- Neumayr G, Pfister R, Mitterbauer G, Eibl G, Hoertnagl H. Effect of competitive marathon cycling on plasma N-terminal pro-brain natriuretic peptide and cardiac troponin T in healthy recreational cyclists. Am J Cardiol 2005;96:732–5.
- Mousavi N, Czarnecki A, Kumar K, Fallah-Rad N, Lytwyn M, Han SY, et al. Relation of biomarkers and cardiac magnetic resonance imaging after marathon running. Am J Cardiol 2009;103:1467–72.
- 22. Frassl W, Kowoll R, Katz N, Speth M, Stangl A, Brechtel L, et al. Cardiac markers (BNP, NT-pro-BNP, troponin I, troponin T, in female amateur runners before and up until three days after a marathon. Clin Lab 2008;54:81–7.
- 23. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:425–30.
- 24. Neilan TG, Januzzi JL, Lee-Lewandrowski E, Ton-Nu TT, Yoerger DM, Jassal DS, et al. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation 2006;114:2325–33.
- 25. Middleton N, Shave R, George K, Whyte G, Forster J, Oxborough D, et al. Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man. Exp Physiol 2006;91:511-9.
- 26. Sumann G, Fries D, Griesmacher A, Falkensammer G,

Klingler A, Koller A, et al. Blood coagulation activation and fibrinolysis during a downhill marathon run. Blood Coagul Fibrinolysis 2007;18:435–40.

- Prisco D, Paniccia R, Bandinelli B, Fedi S, Cellai AP, Liotta AA, et al. Evaluation of clotting and fibrinolytic activation after protracted physical exercise. Thromb Res 1998;89:73–8.
- 28. Kupchak BR, Volk BM, Kunces LJ, Kraemer WJ, Hoffman MD, Phinney SD, Volek JS. Alterations in coagulatory and fibrinolytic systems following an ultramarathon. Eur J Appl Physiol 2013;113:2705-12.
- 29. Sand KL, Flatebo T, Andersen MB, Maghazachi AA. Effects of exercise on leukocytosis and blood hemostasis in 800 healthy young females and males. World J Exp Med 2013;3:11-20.
- 30. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995;130:1276-82.
- Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care 2010;14:R169.
- 32. Mooij CF, de Wit CJ, Graham DA, Powell AJ, Geva T. Reproducibility of MRI measurements of right ventricular size and function in patients with normal and dilated ventricles. J Magn Reson Imaging 2008; 28:67–73.
- 33. Middleton N, Shave R, George K, Whyte G, Hart E, Atkinson G. Left ventricular function immediately following prolonged exercise: a meta-analysis. Med Sci Sports Exerc 2006;38:681–7.
- 34. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J 2008;29:71–8.
- Trivax JE, McCullough PA. Phidippides cardiomyopathy: a review and case illustration. Clin Cardiol 2012;35:69–73.
- 36. Scharhag J, Herrmann M, Urhausen A, Haschke M, Herrmann W, Kindermann W. Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. Am Heart J 2005;150:1128–34.
- 37. George KP, Dawson E, Shave RE, Whyte G, Jones M, Hare E, et al. Left ventricular systolic function and diastolic filling after intermittent high intensity team sports. Br J Sports Med 2004;38:452–6.
- 38. Shave R, Dawson E, Whyte G, George K, Ball D, Collinson P, Gaze D. The cardiospecificity of the third-generation cTnT assay after exercise-induced muscle damage. Med Sci Sports Exerc 2002;34:651–4.
- 39. Dawson EA, Shave R, George K, Whyte G, Ball D, Gaze D, Collinson P. Cardiac drift during prolonged exercise with echocardiographic evidence of reduced diastolic

function of the heart. Eur J Appl Physiol 2005; 94:305-9.

- 40. Shave RE, Dawson E, Whyte G, George K, Gaze D, Collinson P. Effect of prolonged exercise in a hypoxic environment on cardiac function and cardiac troponin t. Br J Sports Med 2004;38:86 – 8.
- 41. Shave R, Dawson E, Whyte G, George K, Nimmo M, Layden J, et al. The impact of prolonged exercise in a cold environment upon cardiac function. Med Sci Sports Exerc 2004;36:1522–7.
- 42. Tulloh L, Robinson D, Patel A, Ware A, Prendergast C, Sullivan D, Pressley L. Raised troponin T and echocardiographic abnormalities after prolonged strenuous exercise-the Australian Ironman Triathlon. Br J Sports Med 2006;40:605–9.
- 43. Shave R, Dawson E, Whyte G, George K, Gaze D, Collinson P. Altered cardiac function and minimal cardiac damage during prolonged exercise. Med Sci Sports Exerci 2004;36:1098–103.
- 44. Shave RE, Dawson E, Whyte G, George K, Ball D, Gaze DC, Collinson PO. Evidence of exercise-induced cardiac dysfunction and elevated cTnT in separate cohorts competing in an ultra-endurance mountain marathon race. Int J Sports Med 2002;23:489–94.
- 45. Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, et al. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J 2001;141:751-8.
- 46. Oomah SR, Mousavi N, Bhullar N, Kumar K, Walker JR, Lytwyn M, et al. The role of three-dimensional echocardiography in the assessment of right ventricular dysfunction after a half marathon: comparison with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2011;24:207–13.
- Baker P, Davies SL, Larkin J, Moult D, Benton S, Roberts A, Harris T. Changes to the cardiac biomarkers of nonelite athletes completing the 2009 London Marathon. Emerg Med J 2014;31:374–9.
- 48. Knebel F, Spethmann S, Schattke S, Dreger H, Schroeckh S, Schimke I, et al. Exercise-induced changes of left ventricular diastolic function in postmenopausal amateur marathon runners: assessment by echocardiography and cardiac biomarkers. Eur J Prev Cardiol 2012;21:782–90.
- 49. Lippi G, Schena F, Salvagno GL, Montagnana M, Gelati M, Tarperi C, et al. Influence of a half-marathon run on NT-proBNP and troponin T. Clin Lab 2008;54:251–4.
- 50. Karlstedt E, Chelvanathan A, Da Silva M, Cleverley K, Kumar K, Bhullar N, et al. The impact of repeated marathon running on cardiovascular function in the aging population. J Cardiovasc Magn Reson 2012;14:58.
- 51. Mingels A, Jacobs L, Michielsen E, Swaanenburg J,

Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101–8.

- 52. Knebel F, Schimke I, Schroeckh S, Peters H, Eddicks S, Schattke S, et al. Myocardial function in older male amateur marathon runners: assessment by tissue Doppler echocardiography, speckle tracking, and cardiac biomarkers. J Am Soc Echocardiogr 2009;22:803–9.
- 53. Jassal DS, Moffat D, Krahn J, Ahmadie R, Fang T, Eschun G, Sharma S. Cardiac injury markers in non-elite marathon runners. Int J Sports Med 2009;30:75-9.
- 54. Saenz AJ, Lee-Lewandrowski E, Wood MJ, Neilan TG, Siegel AJ, Januzzi JL, Lewandrowski KB. Measurement of a plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston marathon. Am J Clin Pathol 2006;126:185-9.
- 55. Leers MP, Schepers R, Baumgarten R. Effects of a longdistance run on cardiac markers in healthy athletes. Clin Chem Lab Med 2006;44:999–1003.
- 56. Whyte G, George K, Shave R, Dawson E, Stephenson C, Edwards B, et al. Impact of marathon running on cardiac structure and function in recreational runners. Clin Sci (Lond) 2005;108:73–80.
- 57. George K, Whyte G, Stephenson C, Shave R, Dawson E, Edwards B, et al. Postexercise left ventricular function and cTnT in recreational marathon runners. Med Sci Sports Exerc 2004;36:1709–15.
- 58. Shave RE, Dawson E, Whyte PG, George K, Ball D, Gaze CD, Collinson P. Cardiac troponin T in female athletes during a two-day mountain marathon. Scott Med J 2003;48:41-2.
- 59. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002;48:1097–100.
- 60. Middleton N, Shave R, George K, Whyte G, Simpson R, Florida-James G, Gaze D. Impact of repeated prolonged exercise bouts on cardiac function and biomarkers. Med Sci Sports Exerc 2007;39:83–90.
- Wedin JO, Henriksson AE. Postgame elevation of cardiac markers among elite floorball players. Scand J Med Sci Sports 2015;25:495–500.
- 62. Aagaard P, Sahlen A, Bergfeldt L, Braunschweig F. Heart rate and its variability in response to runningassociations with troponin. Med Sci Sports Exerc 2014;46:1624-30.
- 63. Scherr J, Braun S, Schuster T, Hartmann C, Moehlenkamp S, Wolfarth B, et al. 72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon. Med Sci Sports Exerc 2011;43:1819–27.
- 64. Serrano Ostariz E, Lopez Ramon M, Cremades Arroyos

D, Izquierdo Alvarez S, Catalan Edo P, Baquer Sahun C, Legaz Arrese A. Post-exercise left ventricular dysfunction measured after a long-duration cycling event. BMC Res Notes 2013;6:211.

- 65. Salvagno GL, Schena F, Gelati M, Danese E, Cervellin G, Guidi GC, Lippi G. The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon. Clin Chem Lab Med 2014;52:267–72.
- 66. Eijsvogels TM, Hoogerwerf MD, Maessen MF, Seeger JP, George KP, Hopman MT, Thijssen DH. Predictors of cardiac troponin release after a marathon. J Sci Med Sport 2015;18:88–92.
- 67. Legaz-Arrese A, George K, Carranza-Garcia LE, Munguia-Izquierdo D, Moros-Garcia T, Serrano-Ostariz E. The impact of exercise intensity on the release of cardiac biomarkers in marathon runners. Eur J Appl Physiol 2011;111:2961–7.
- 68. O'Hanlon R, Wilson M, Wage R, Smith G, Alpendurada FD, Wong J, et al. Troponin release following endurance exercise: is inflammation the cause? A cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2010;12:38.
- 69. Banfi G, Lippi G, Susta D, Barassi A, D'Eril GM, Dogliotti G, Corsi MM. NT-proBNP concentrations in mountain marathoners. J Strength Cond Res 2010;24:1369–72.
- 70. Trivax JE, Franklin BA, Goldstein JA, Chinnaiyan KM, Gallagher MJ, deJong AT, et al. Acute cardiac effects of marathon running. J Appl Physiol (1985) 2010; 108:1148–53.
- 71. Smith JE, Garbutt G, Lopes P, Pedoe DT. Effects of prolonged strenuous exercise (marathon running) on biochemical and haematological markers used in the investigation of patients in the emergency department. Br J Sports Med 2004;38:292-4.
- Aagaard P, Sahlen A, Braunschweig F. Performance trends and cardiac biomarkers in a 30-km cross-country race, 1993–2007. Med Sci Sports Exerc 2012; 44:894-9.
- 73. Parker BA, Augeri AL, Capizzi JA, Ballard KD, Kupchak BR, Volek JS, et al. Effect of marathon run and air travel on pre- and post-run soluble D-dimer, microparticle procoagulant activity, and p-selectin levels. Am J Cardiol 2012;109:1521–5.
- 74. Rifai N, Douglas PS, O'Toole M, Rimm E, Ginsburg GS. Cardiac troponin T and I, echocardiographic [correction of electrocardiographic] wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. Am J Cardiol 1999;83:1085–9.
- Douglas PS, O'Toole ML, Woolard J. Regional wall motion abnormalities after prolonged exercise in the normal left ventricle. Circulation 1990;82:2108–14.